Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 9554319

Bupropion sustained release: side effect profile.

E C Settle
View original source ↗Export metadata ↓

Abstract

Bupropion IR (immediate release) has been on the market since 1988 and is an effective and usually well-tolerated antidepressant. In late 1996, a new sustained-release formulation, bupropion SR, was approved and is now available. Compared with the IR formulation, the SR formulation demonstrates similar efficacy and has been found to have similar, but to some degree fewer, side effects. Its efficacy is similar to that of other newer antidepressants. Side effects of bupropion SR are limited and are not dissimilar to those of the serotonergic antidepressants; however, bupropion SR produces neither substantial sexual side effects nor drug interactions. Study data demonstrate that seizure incidence, which is a concern with high-dose IR, is substantially lower with the new SR formulation.

Explore related subjects

Antidepressive Agents, Second-GenerationAntidepressive Agents, TricyclicBupropionDelayed-Action PreparationsDepressive DisorderDizzinessDose-Response Relationship, DrugDrug Administration ScheduleHeadacheHumansNauseaSeizuresSleep Initiation and Maintenance DisordersWeight GainComparative StudyJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E C Settle. 1998. Bupropion sustained release: side effect profile.. https://pubmed.ncbi.nlm.nih.gov/9554319/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Latent-variable models for longitudinal data with bivariate ordinal outcomes.

We use the concept of latent variables to derive the joint distribution of bivariate ordinal outcomes, and then extend the model to allow for longitudinal data. Specifically, we relate the observed ordinal outcomes using threshold values to a bivariate latent variable, which is then modelled as a linear mixed model. Random effects terms are used to tie all together repeated observations from the same subject. The cross-sectional association between the two outcomes is modelled through the correlation coefficient of the bivariate latent variable, conditional on random effects. Assuming conditional independence given random effects, the marginal likelihood, under the missing data at random assumption, is approximated using an adaptive Gaussian quadrature for numerical integration. The model provides fixed effects parameters that are subject-specific, but retain the population-averaged interpretation when properly scaled. This is particularly well suited for the situation in which population comparisons and individual level contrasts are of equal importance. Data from a psychiatric trial, the Fluvoxamine (an antidepressant drug) study, are used to illustrate the methodology.

Antidepressive Agents, Second-Generation↗
PubMed2007

Acute dystonia resulting from abrupt bupropion discontinuation.

Acute dystonia is commonly associated with high-potency antipsychotics. Some cases of acute dystonia had been reported to be associated with antidepressant. However, only few reported cases are related to bupropion. As reported herein, the patient with major depression suffered from acute dystonia twice, which resulted from abrupt bupropion discontinuation. The first episode occurred when medicament was shifted from bupropion to duloxetine abruptly. The patient was requested with nothing per mouth (NPO) due to panendoscopic examination. Therefore, the second one emerged after the patient was suspended from two doses of bupropion. The symptoms of dysphagia, trismus and torticollis in these two episodes were resolved after bupropion reinstitution or biperiden injection. So far as we know by our documents, this is the first report concerning an acute dystonia resulting from bupropion discontinuation.

Antidepressive Agents, Second-Generation↗
PubMed2007

Genetic screening for SSRI drug response among those with major depression: great promise and unseen perils.

This article examines evidence for the potential benefit of genetic testing for SSRI response, as well as potential ethical and practical implications of the implementation of this test into standard psychiatric practice. We reviewed three areas of the literature: the burden of treatment-resistant and treatment-intolerant major depressive disorders, the evidence for the value of genetic testing to predict drug response, and the ethical and practical issues of genetic testing in usual care. Treatment resistance and treatment intolerance are common for persons treated with selective serotonin reuptake inhibitors (SSRIs) and are associated with both financial and quality-of-life costs. There is strong evidence from association studies that some polymorphisms are associated with SSRI response. However, no randomized trials have yet tested the efficacy of genetic tests to improve outcome in those with treatment resistance or treatment intolerance to SSRIs. Given the nonspecific nature of the test proposed, several ethical concerns are also involved with administering the genetic tests to patients. A randomized trial comparing response in those treated with standard psychiatric care and in those treated with psychiatric care tailored as a result of genetic test results should be completed before the implementation of these tests can be considered. Additionally, the ethical and practical questions concerning the tests must be addressed now, so that the potential impact of these tests on patient care can be well understood prior to adoption in standard practice.

Antidepressive Agents, Second-Generation↗